(Q46890745)

26 December 2017

meta-analysis

0 references

title

A meta-analysis of the effect of thiazolidinediones on blood pressure (English)

1 reference

26 December 2017

1 reference

Rehan Qayyum

1

1 reference

26 December 2017

Jurga Adomaityte

series ordinal

2

1 reference

26 December 2017

publication date

1 January 2006

1 reference

26 December 2017

Journal of Clinical Hypertension

published in

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

19-28

1 reference

26 December 2017

The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Pioglitazone Increases Serum Magnesium Levels in Glucose-Intolerant Subjects. A Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone Lowers Blood Pressure and Increases Arterial Compliance in Postmenopausal Women With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Comparison of pioglitazone and metformin efficacy using homeostasis model assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Pioglitazone attenuates diet-induced hypertension in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04784.X

10.1111/J.1524-6175.2005.04784.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017